NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,258.83 mln
Float72.76 mln
Earnings Date08/11/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
47
/ 100
In line with market
Debt / Equity
0.00
Debt-free
ROE
-43.89
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Corvus Pharmaceuticals is a US-based clinical-stage company focused on developing treatments that work by targeting key proteins involved in immune system function. Its pipeline includes three main drug candidates currently in clinical trials for conditions ranging from certain cancers to inflammatory and autoimmune diseases. The company supports its research through licensing partnerships with several academic and commercial organizations. Founded in 2014 and headquartered in South San Francisco, California, Corvus is working to bring forward a new generation of immune-based therapies.
